Special Issue

Topic: Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma

A Special Issue of Hepatoma Research

ISSN 2454-2520 (Online) 2394-5079 (Print)

Submission deadline: 15 Feb 2023

Guest Editor(s)

Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, FACS, FSSO, FRACS (Hon.)

Professor and Chair, Department of Surgery;
The Urban Meyer III and Shelley Meyer Chair for Cancer Research;
Professor of Surgery, Oncology, and Health Services Management and Policy;
Surgeon in Chief, The Ohio State University Wexner Medical Center;
The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

Special Issue Introduction



Special Issue Webinar: Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma is a neoplasm of biliary epithelial origin, which is generally categorized according to anatomic localization: intra-hepatic (iCCA), hilar, and extra-hepatic. iCCA accounts for 10%-15% of all primary liver cancers worldwide and is the second most common primary liver malignancy after hepatocellular carcinoma with a varying incidence worldwide. There are several risk factors associated with iCCA including older age and female sex. Other risk factors include primary sclerosing cholangitis, hepatolithiasis, choledochal cysts, primary biliary cirrhosis, parasitic biliary infection with Clonorchis sinensis or Opisthorchis viverrini, inflammatory bowel disease, as well as non-alcoholic fatty liver disease. Despite recent developments in imaging modalities and laboratory diagnostic tests, the diagnosis of the tumor is often delayed until advanced stages when surgery cannot be offered. Therefore, iCCA patients generally have poor prognosis with a short overall survival. Treatment of advanced iCCA typically includes systemic therapy with traditional cytotoxic agents, or targeted agents depending on the mutational status of the tumor. For patients with disease amenable to surgery, treatment involves a margin negative hepatic resection, lymphadenectomy, as well as consideration of adjuvant therapy. The objective of this Special Issue is to characterize the progress made in treating iCCA, as well as highlight the emerging systemic and locoregional treatments of iCCA.

This Special Issue welcomes original or review manuscripts, perspectives, opinions and commentaries on different aspects of iCCA, including but not limited to:
1. Epidemiology
2. Pathogenesis
3. Imaging
4. Role of preoperative chemotherapy
5. Surgical resection and intraoperative considerations
6. Role of lymphadenectomy
7. Use of thermal ablation
8. Hepatic Artery Pump therapy
9. Intra-arterial / Y90 therapy
10. Novel biomarkers
11. Cytotoxic chemotherapy for advanced and adjuvant indications
12.Targeted mutation-based therapy

Submission Deadline

15 Feb 2023

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/hr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=hr&SpecialIssueId=hr220928
Submission Deadline: 15 Feb 2023
Contacts: Ada Zhong, Assistant Editor, editor_Ada@hrjournal.net

Published Articles

Advanced and emerging radiation therapy approaches for intrahepatic cholangiocarcinoma
Open Access Review
Views: Downloads:
Download PDF
The role of liver transplant for intrahepatic cholangiocarcinoma: the UK NHSBT liver advisory group pilot programme
Open Access Original Article
Views: Downloads:
Download PDF
Liver transplantation for intrahepatic cholangiocarcinoma: a narrative review of the latest advances
Open Access Review
Views: Downloads:
Download PDF
Surgical management of intrahepatic cholangiocarcinoma
Open Access Review
Views: Downloads:
Download PDF
Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/